MC4R and obesity due to melanocortin 4 receptor deficiency: Furthermore, there is now an extension trial for up to 5 years to study the safety and tolerability of continued setmelanotide in patients with obesity associated with genetic defects upstream of the MC4R in the leptin–melanocortin pathway.80